Make your scheduling
- All Posts
- Sem categoria
March 18, 2026 • 8 min read Much has been said about the agreement between Mercosur and the European Union, often from the most obvious perspective: tariff reduction. In healthcare, however, that view’s incomplete. What’s unfolding isn’t simply a trade liberalization process. It’s a structural reconfiguration of how medical devices and pharmaceuticals enter Brazil. And more importantly? Who captures value along the way. The Starting Point: Inefficiency by Design Today, the import structure in healthcare still carries significant inefficiencies. European medical devices reach Brazil burdened by tariffs, high logistics costs, and long distribution chains. Pharmaceuticals, in addition to taxation, face further constraints related to intellectual property and regulatory requirements. The outcome’s predictable: inflated prices and...
For years, international expansion in the medical device sector followed a predictable yet inefficient path. Each new market meant restarting...
Getting regulatory approval in Brazil feels like the finish line for many manufacturers. Months of preparation. Documentation. Technical files. Interactions with ANVISA. When the approval finally comes through, the natural reaction is simple: Great. Now we can start selling. But Brazil doesn’t quite work that way. Regulatory approval is important. Absolutely necessary. It’s just not the moment the market opens. In reality, approval is the moment the next phase begins. Approval allows entry. It doesn’t guarantee adoption. We’ve watched this pattern many times. A manufacturer receives ANVISA approval and expects the commercial process to move quickly. After all, the product is now legally authorized in the country. Hospitals should be ready. Distributors should be eager. Sales should follow. And yet, months later, adoption is slower than expected. Sometimes much slower. Why? Because hospital adoption in Brazil depends on a set of dynamics that exist beyond regulatory approval. Understanding those dynamics early makes an enormous difference. Hospitals don’t buy approvals. They buy solutions. From a regulatory perspective, approval means the product meets safety and performance requirements. From a hospital’s perspective, that’s just the starting point. Procurement teams, clinical committees,...
Most manufacturers looking at Brazil for the first time assume the regulatory hurdle is the main challenge. ANVISA approval. Documentation....
Brazil is widely recognized as the largest healthcare market in Latin America and one of the most promising destinations for...
When Time Equals Value: How Efficient Regulation Drives Innovation and Growth In healthcare, every regulatory decision carries economic weight. From the moment...
In the highly regulated world of healthcare, success depends not only on technical expertise, but on trust, transparency, and partnership. Manufacturers,...
Brazil’s healthcare sector is entering a new era, one defined by digital transformation, medical technology, and intelligent systems that are...
The Brazilian Health Regulatory Agency ANVISA has issued Normative Instruction No. 426, dated February 13, 2026, establishing the requirements for data submission...
